Literature DB >> 2144206

Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.

F Keuppens1, L Denis, P Smith, A P Carvalho, D Newling, A Bond, R Sylvester, M De Pauw, K Vermeylen, P Ongena.   

Abstract

A total of 327 patients with metastatic prostatic cancer were randomized to either bilateral orchiectomy or treatment with zoladex depot supplemented by flutamide 250 mg 3 qid. Statistically significant increases in time to subjective and objective progression were recorded in favor of the combination treatment. No differences in time to death by cancer or overall death were recorded. The clinical significance of these differences will be reassessed once additional follow-up is available and further analysis of the overall clinical material has been carried out.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144206     DOI: 10.1002/cncr.1990.66.s5.1045

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Cyproterone acetate monotherapy in advanced prostatic carcinoma.

Authors:  O Kayigil; O Atahan; A Metin
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

2.  Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.

Authors:  Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Thilo Spruss; Anton Maucher; Erwin von Angerer; Claus D Schiller; Martin R Schneider; Ronald Gust; Helmut Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-06       Impact factor: 4.553

Review 3.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 4.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

Review 5.  Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.

Authors:  R N Brogden; P Chrisp
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

Review 6.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 7.  Drug therapy of prostatic cancer.

Authors:  R P Huben; S D Perrapato
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.